Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension by Brash, Lauren et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Short-Term Hemodynamic Effects of Apelin in Patients With
Pulmonary Arterial Hypertension
Citation for published version:
Brash, L, Barnes, GD, Brewis, MJ, Church, AC, Gibbs, SJ, Howard, LSGE, Jayasekera, G, Johnson, MK,
McGlinchey, N, Onorato, J, Simpson, J, Stirrat, C, Thomson, S, Watson, G, Wilkins, MR, Xu, C, Welsh, DJ,
Newby, DE & Peacock, AJ 2018, 'Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary
Arterial Hypertension', JACC: Basic to Translational Science, vol. 3, no. 2, pp. 176-186.
https://doi.org/10.1016/j.jacbts.2018.01.013
Digital Object Identifier (DOI):
10.1016/j.jacbts.2018.01.013
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Version created as part of publication process; publisher's layout; not normally made publicly available
Published In:
JACC: Basic to Translational Science
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E VO L . - , N O . - , 2 0 1 8
ª 2 0 1 8 T H E A U T H O R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E A M E R I C A N
C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .NEW RESEARCH PAPERShort-Term Hemodynamic Effects
of Apelin in Patients With
Pulmonary Arterial Hypertension
Lauren Brash, MD,a Gareth D. Barnes, MD,c Melanie J. Brewis, MD,a A. Colin Church, MD,a Simon J. Gibbs, MD,c
Luke S.G.E. Howard, MD,c Geeshath Jayasekera, MBCHB,a Martin K. Johnson, MD,a Neil McGlinchey, MBCHB,a
Joelle Onorato, PHD,d Joanne Simpson, MD,a Colin Stirrat, MD,b Stephen Thomson, MBCHB,a Geoffrey Watson, MD,c
Martin R. Wilkins, MD,c Carrie Xu, MS,d David J. Welsh, PHD,a David E. Newby, MD,b Andrew J. Peacock, MDaVISUAL ABSTRACTIS
F
F
cN
NBrash, L. et al. J Am Coll Cardiol Basic Trans Science. 2018;-(-):-–-.SN 2452-302X
rom the aScottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow
oundation/University of Edinburgh Centre for Cardiovascular Science, University of Edinbu
ational PulmonaryHypertension Service–London, Department of Cardiac Sciences, Hammersmith
HSTrust,London,UnitedKingdom;andthedBristol-Myers Squibb Company, Discovery R&D, PHIGHLIGHTS
 The effects of apelin on pulmonary
hemodynamics in patients with PAH are
unknown.
 Systemic infusion caused a significant
reduction in pulmonary vascular
resistance and increase in cardiac output
without a change in heart rate or systemic
vascular resistance.
 This effect was most prominent in the
subgroup of patients receiving
concomitant PDE5 inhibition.
 Apelin agonism is a novel potential
therapeutic target for PAH.https://doi.org/10.1016/j.jacbts.2018.01.013
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reApelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves
pulmonary arterial hypertension (PAH) in animal models. Here, the authors examined the short-term
pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH. In a double-blind randomized
crossover study, 19 patients with PAH received intravenous (Pyr1)apelin-13 and matched saline placebo
during invasive right heart catheterization. (Pyr1)apelin-13 infusion caused a reduction in pulmonary
vascular resistance and increased cardiac output. This effect was accentuated in the subgroup of patients
receiving concomitant phosphodiesterase type 5 inhibition. Apelin agonism is a novel potential therapeutic
target for PAH. (Effects of Apelin on the Lung Circulation in Pulmonary Hypertension; NCT01457170)
(J Am Coll Cardiol Basic Trans Science 2018;-:-–-) © 2018 The Authors. Published by Elsevier on behalf of the
American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).P ulmonary arterial hypertension (PAH) is a dis-ease in which functional and structuralchanges of the pulmonary vasculature cause
a progressive increase in pulmonary vascular resis-
tance (PVR), leading to pressure overload of the right
ventricle and premature death. This is thought to
arise from an imbalance between vasodilator and
vasoconstrictor mediators. In addition, structural
changes of the vessel wall (remodeling) occur due to
proliferation of the endothelium, vascular smooth
muscle cells, and fibroblasts leading to progressive
obstruction of the pulmonary vascular bed (1).
Although there are current therapies in PAH targeting
the nitric oxide (NO)-cyclic GMP, endothelin, and
prostacyclin pathways, there remains an unaccept-
ably low 3-year survival of 63% (2). Further novel
therapeutic interventions are therefore needed to
improve the outlook in this progressive fatal
condition.
Apelin is an endogenous peptide that was first
discovered in 1998. It binds to a previously orphaned
G-protein-coupled receptor, now termed the apelin
receptor (3). Apelin receptors are present on endo-
thelial cells, vascular smooth muscle cells, and car-
diomyocytes (4). In preclinical models, apelinudy was provided by a British Heart Foundation Project Gran
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and cardiac contractility leading to vasorelaxation (5),
falls in arterial blood pressure and systemic venous
tone (6–9), and potent inotropism (10) with increased
cardiac contractility.
We have previously conducted clinical studies
looking at the effects of apelin in healthy volunteers
and patients with heart failure (11,12). We showed
apelin to be a direct coronary and peripheral vasodi-
lator, to increase myocardial contractility, and to
reduce peak and end-diastolic left ventricular pressure
(13).We also demonstrated that these inotropic actions
were maintained during prolonged 6-h infusions (12).
Apelin infusion improves pulmonary vascular hemo-
dynamics in 2 animal models of PAH (14,15), and this
may translate into benefit for patients with PAH by
reducing PVR and increasing cardiac output (CO). Given
these preclinical and clinical data, we sought to deter-
mine the short-term pulmonary hemodynamic effects of
intravenous apelin infusion in patients with PAH.
METHODS
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3patients with PAH. All studies were performed with
written informed consent of the participants, with the
approval of the local ethics committee, and in accor-
dance with the Declaration of Helsinki.
SUBJECTS. Patients with PAHwere recruited from the
Golden Jubilee National Hospital in Glasgow and
Hammersmith Hospital in London, both of which are
specialist national centers for PAH. Patients were
either new patients attending for diagnostic assess-
ment or patients with known PAH who have been
receiving stable doses of approved mono- or combi-
nation PAH therapy for at least 2 months before study.
Inclusion criteria were: 1) PAH that is idiopathic,
associated with drugs/toxins, associated with con-
nective tissue disease, or heritable; 2)meanpulmonary
arterial pressure $25 mm Hg, pulmonary capillary
wedge pressure #15 mm Hg with a normal or reduced
CO; and 3) stableWorld Health Organization functional
capacity of grade II to IV for 3 months before study.
PAH patients were excluded if they had significant left
ventricular dysfunction, chronic lung disease (FEV1/
FVC <60%; abnormal lungs on computed tomogra-
phy), or chronic thromboembolic pulmonary hyper-
tension. Further exclusion criteria included bleeding
diathesis, women of childbearing potential, systolic
blood pressure>190mmHg or<100mmHg,malignant
arrhythmias, renal or hepatic failure, or hemodynam-
ically significant valvular heart disease.
All subjects fasted for at least 4 h before the pro-
cedure and avoided alcohol or caffeine for 24 h before
the study. Patients delayed taking routine medication
on the morning of the right heart catheterization until
completion of the study protocol.
DRUGS. The effects of apelin agonism were deter-
mined using synthetic-grade (Pyr1)apelin-13 (Clinalfa,
Laufelfingen, Switzerland) (11,13). This was adminis-
tered after dissolution in 0.9% physiological saline
(Baxter, Deerfield, Illinois) under aseptic conditions
on the study day.
PLASMA APELIN CONCENTRATIONS. In a group of
patients (n ¼ 8), plasma apelin concentrations were
measured to ensure that the infusion had raised apelin
levels. Plasma (Pyr1)apelin-13 concentration was deter-
mined using immunoprecipitation followed by liquid
chromatography/mass spectrometry/mass spectrometry
(LC/MS/MS) analysis. Briefly, human plasma (500 ml, kept
on ice) was first treated with 2  0.75 ml cold 0.1% formic
acid (FA) in isopropanol. Following centrifugation, the
supernatants were dried under nitrogen then recon-
stituted in phosphate buffered saline/Tween.
For immunoprecipitation, an anti–(pyr1)apelin-13 mono-
clonal antibody (Bristol-Myers Squibb, Princeton, New
Jersey) was bound to high capacity Protein G magneticbeads (Promega, Madison, Wisconsin). The reconstituted
human plasma was incubated overnight at room
temperature with 25 ml of the antibody-bead slurry. After
multiplewashes, (pyr1)apelin-13was eluted from thebead
complex using 0.1% bovine serum albumin/0.1% FA in
90:10 water to methanol. The eluates were analyzed by
LC/MS/MS on a Sciex API6500 mass spectrometer
(Sciex, Redwood City, California) coupled to a Shimadzu
Nexera X2 LC-30AD pump and Sil-30AC MP autosampler
(both Shimadzu, Kyoto, Japan). Gradient elution was
performed on a Waters BEH300 2.1  50 mm column
(Waters, Milford, Massachusetts) using a mobile phase of
0.1% FA and 0.1% FA in acetonitrile. The transitions
monitored were m/z 384.2/424.8 for (pyr1)apelin-13
and m/z 387.4/426.8 for the internal standard
(13C,15N-(pyr1)apelin-13 from Innovagen [Lund, Sweden]).
For normalization, the internal standard was added to all
human plasma and calibration curve samples before
starting thesampleextractionprotocol.Calibrationcurves
were generated by spiking (pyr1)apelin-13 standard into
blank human plasma (purchased from Bioreclamation
[Westbury, New York] and heated at 37C overnight to
remove any endogenous apelin) and extracting apelin
following the identical sample extraction protocol
described above. The concentration of (pyr1)apelin-13 in
clinical human plasma was calculated on the basis of the
calibration curves, using the peak area ratio of measured
apelin to internal standard. The limit of quantification of
the assay was approximately 4 pmol/l.
PULMONARY HEMODYNAMIC ASSESSMENT. Resting
hemodynamic evaluation was performed as per
routine protocol and included right atrial pressure,
right ventricular pressure, pulmonary arterial pres-
sure, and pulmonary arterial wedge pressure.
Cardiac output (CO) was measured by either ther-
modilution (Golden Jubilee National Hospital) or the
Fick principle (Hammersmith Hospital). Thermodilution
CO was taken from the mean of at least 3 values that
differed by <10%. The Fick method determined CO by
arterial blood sampling and sampling of mixed venous
blood from the pulmonary artery via the Swan-Ganz
catheter. Oxygen consumption was measured using
the Fitmate (Cosmed, Rome, Italy). CO was then calcu-
lated using the modified Fick equation: CO ¼ O2 con-
sumption/(O2 content of arterial blood  O2 content of
mixed venous blood). PVR was calculated by dividing
the difference between mean pulmonary artery and
pulmonary arterial wedge pressures by the CO.
PROTOCOL. Each study was conducted in a quiet and
temperature-controlled investigation suite with sub-
jects in the supine position. Heart rate, electrocar-
diogram, pulse oximetry, and systemic arterial blood
pressure were monitored continuously throughout.
TABLE 1 Demographic and Hemodynamic Characteristics
at Baseline
Age, yrs 51.8  3.2
Sex
Male 7/19 (37)
Female 12/19 (63)
Diagnosis
IPAH 17/19 (89)
CTD PH 2/19 (11)
Smoker
Never 11/19 (58)
Current 4/19 (21)
Ex 4/19 (21)
Hb, g/dl 14.1  0.4
BMI, kg/m2 29.1  1.1
Medication
PDE5i 11/19 (58)
ERA 9/19 (47)
Prostacycline 3/19 (16)
Treatment naive 5/19 (26)
Baseline hemodynamics
PVR, WU 9.1  0.9
CO, l/min 4.8  0.3
Heart rate, beats/min 72  2.9
mPAP, mm Hg 48.1  2.7
SV, ml 69.8  4.9
MAP, mm Hg 87.8  2.6
RAP, mm Hg 6.1  0.8
PAWP, mm Hg 7.6  0.7
SVR, dyn 1,413  74.1
Values are mean  SEM or n/N (%).
BMI ¼ body mass index; CO ¼ cardiac output; CTD PH ¼ connective tissue
disease pulmonary hypertension; ERA ¼ endothelin receptor antagonist; Hb ¼
hemoglobin; IPAH ¼ idiopathic pulmonary arterial hypertension; MAP ¼ mean
arterial pressure; mPAP ¼ mean pulmonary artery pressure; NYHA ¼ New York
Heart Association; PAWP ¼ pulmonary arterial wedge pressure; PDE5i ¼ phos-
phodiesterase inhibitor; PVR ¼ pulmonary vascular resistance; RAP ¼ right atrial
pressure; SV ¼ stroke volume; SVR ¼ systemic vascular resistance.
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4An 8-F sheath was placed in the right internal jugular
vein using ultrasound imaging, or brachial vein using
standard aseptic techniques. A Swan-Ganz catheter
(7-F, 2 lumen, thermodilution pressure-measuring
tipped catheter; Edwards Lifesciences, Irvine,
California) was passed into the pulmonary artery.
In a randomized, double-blinded, crossover
design, each participant received three 5-min
intravenous infusions of ascending doses of (Pyr1)
apelin-13 at 10, 30, and 100 nmol/min (11,13) or
matched saline placebo. The order of (Pyr1)apelin-13
or saline placebo was randomized. Hemodynamic
data were collected at the end of each 5-min infusion
period. The apelin and saline placebo infusions were
separated by a 30-min washout period before
commencing the second infusion period. A 30-min
washout was chosen on the basis of our previous
clinical studies that showed that apelin was rapidly
cleared from the circulation with a short plasma
half-life of no longer than 8 min (11).
EXERCISE TESTING PROTOCOL. In the days before
right heart catheterization, subjects underwent a pro-
gressive incremental exercise test on an ergometer to
determine the maximal exercise capacity, starting at 0 W
for 3 min and adding 10 W every minute until the
symptom-limited maximum was reached. This was used
to calculate exercise work rates for individuals during
the exercise component of the study. On the day of
study and at the end of each 15-min infusion period
(100 nmol/min of (Pyr1)apelin-13 or matched saline pla-
cebo), participants underwent an exercise protocol. This
exercise study was carried out in the supine position
with a cycle ergometer secured to the catheterization
table (Golden Jubilee National Hospital) or on an echo-
cardiogram exercise stress table (Cranlea Human Per-
formance, United Kingdom). The patient was instructed
to pedal at a rate of 60 rpm. Hemodynamic measure-
ments were taken at rest, during unloaded exercise and
during loaded exercise (20% and 40% of the previously
determined maximal exercise capacity during their
progressive incremental exercise test).
DATA AND STATISTICAL ANALYSIS. The primary
endpoint of the study was the change in PVR from
baseline. This is a standard andwell-validated primary
or secondary endpoint in clinical trials for PAH thera-
pies. Secondary outcomes included change in CO and
systemic vascular resistance (SVR). On the basis of
previous studies (16–21) investigating the short-term
pulmonary hemodynamic effects of PAH treatments,
we calculated that to see an effect size of 20% (SD of
2.13 WU/149 dyne.s.cm5), we would need a sample
size of around 21 (21) at 80% power and 2-sided
p < 0.05. Data are reported as mean  SEM andanalyzed with repeated-measures analysis of variance
with post hoc Bonferroni corrections (GraphPad Prism
7 software, GraphPad Software, San Diego, California).
Statistical significance was taken as 2-sided p < 0.05.
RESULTS
Study participants were predominantly female and
middle-aged (Table 1). All studies were well tolerated
with no serious adverse events or electrocardio-
graphic changes during apelin administration. Nine-
teen subjects were included in the analysis (2 subjects
were excluded because of protocol deviations).
Before apelin infusion, there were no detectable basal
plasma apelin concentrations in patients with PAH.
Following infusion with (Pyr1)apelin-13, there was a
marked increase in plasma apelin concentrations
(peak concentration, 10,681  4,184 pmol/l). The in-
dividual data for each study participant are included
in Table 2.
TABLE 2 Hemodynamic Data
Apelin, nmol/min Saline Placebo, min
Baseline 10 30 100 Baseline 5 10 15
All subjects (n ¼ 19)
PVR, WU 9.1  0.9 7.9  0.7 8.2  0.7 8.5  0.8 9.2  0.8 9.0  0.9 9.6  1.0 9.4  1.0
CO, l/min 4.8  0.3 5.3  0.3 5.3  0.3 5.2  0.3 4.8  0.2 4.9  0.3 4.7  0.3 4.8  0.3
HR, beats/min 72  2.9 73  2.9 72  3.0 72  3.2 72  3.1 73  3.5 73  3.5 74  3.6
mPAP, mm Hg 48  2.7 46  2.9 47  3.0 48  2.9 49  2.7 48  2.7 49  3.0 48  3.1
SV, ml 70  4.9 75  4.8 77  4.8 77  5.7 70  4.8 70  4.8 69  5.0 69  5.3
MAP, mm Hg 88  2.6 85  2.0 88  2.9 87  2.5 88  2.8 87  2.5 87  2.5 88  2.9
SVR, dyne 1,413  74 1,245  70 1,303  84 1,326  95 1,433  94 1,421  110 1,447  101 1,440  99
Treatment naive (n ¼ 5)
PVR, WU 7.4  1.2 6.6  01.0 7.2  1.3 7.2  1.3 8.1  1.0 7.4  1.3 7.4  1.4 7.2  1.4
CO, l/min 5.1  0.4 5.3  0.5 5.2  0.6 5.6  0.7 5.0  0.5 5.1  0.6 5.1  0.6 5.3  0.7
HR, beats/min 64  4.7 62  5.5 61  4.5 64  5.6 64  6.5 66  6.8 65  5.6 66  5.8
mPAP, mm Hg 43  2.7 41  3.1 42  4.3 43  3.6 45  2.4 42  4.0 41  3.6 40  4.0
SV, ml 81  9.3 88  10.1 86  9.5 88  11.2 80  9.0 79  8.0 80  9.5 82  12.3
MAP, mm Hg 85  2.7 81  3.1 88  2.9 87  4.5 85  3.2 84  3.7 84  5.4 81  3.5
SVR, dyne 1,280  103 1,201  182 1,354  226 1,283  283 1,365  227 1,329  244 1,363  294 1,266  240
On treatment (n ¼ 14)
PVR, WU 9.7  1.2 8.4  0.8 8.5  0.9 8.9  0.9 9.6  1.1 9.6  1.1 10.4  1.2 10.2  1.3
CO, l/min 4.8  0.3 5.3  0.3 5.3  0.3 5.1  0.3 4.8  0.3 4.8  0.3 4.6  0.3 4.7  0.3
HR, beats/min 75  3.3 77  2.9 76  3.3 75  3.6 75  3.4 75  4.0 76  4.1 77  4.2
mPAP, mm Hg 50  3.4 48  3.6 49  3.8 50  3.6 50  3.6 50  3.3 51  3.6 51  3.7
SV, ml 66  5.6 71  5.1 73  5.5 72  6.5 66  5.6 67  5.8 65  5.6 65  5.5
MAP, mm Hg 89  3.5 86  2.5 88  3.8 87  3.0 89  3.7 88  3.1 88  2.8 90  3.6
SVR, dyne 1,461  92 1,261  74 1,285  87 1,339  99 1,457  104 1,454  125 1,477  97 1,502  104
On PDE5 inhibitors
(n ¼ 11)
PVR, WU 10.9  1.2 9.1  0.9 9.2  1.0 10.8  1.0 10.6  1.1 10.6  1.2 11.6  1.3 11.4  1.4
CO, l/min 4.5  0.3 5.1  0.3 5.1  0.4 4.9  0.4 4.5  0.3 4.5  0.3 4.3  0.3 4.4  0.3
HR, beats/min 75  3.8 78  3.3 76  3.7 76  4.3 75  4.0 75  4.7 76  4.8 77  5.0
mPAP, mm Hg 52  3.9 51  3.9 52  4.2 52  4.0 53  3.7 52  3.5 54  3.7 54  3.9
SV, ml 62  6.7 68  6.2 71  6.8 69.  8.0 63  6.8 64  7.0 61  6.8 62  6.6
MAP, mm Hg 85  3.0 85  2.3 85  2.2 85  2.2 87  2.7 86  2.1 86  2.8 87  2.5
SVR, dyne 1,494  114 1,289  86 1,290  92 1,382  108 1,495  116 1,513  149 1,543  112 1,542  120
On treatment without
PDE5 inhibitors (n ¼ 3)
PVR, WU 5.3  1.3 5.6  1.4 5.9  1.4 5.6  1.4 5.6  1.5 5.9  1.4 6.2  1.6 5.9  1.4
CO, l/min 5.8  0.6 6.0  0.7 6.1  0.4 5.9  0.5 5.6  0.2 5.7  0.1 5.6  0.3 5.7  0.3
HR, beats/min 73  7.7 72  6.8 73  7.8 70  6.8 74  7.9 74  8.5 74  8.2 76  9.1
mPAP, mm Hg 41.  5.9 39  7.4 40  8.0 41  8.2 40  8.5 41  8.1 42  9.5 42  8.7
SV, ml 80  0.6 83  1.7 84  3.5 85  3.4 77  5.3 79  6.9 77  3.7 76  5.1
MAP, mm Hg 103  8.4 92  8.2 101  15.6 91  12.9 98  15.2 95  13.8 93  9.0 102  14.2
SVR, dyne 1,342  109 1,157  160 1,267  276 1,178  257 1,318  256 1,238  195 1,238  149 1,357  233
Treatment naive and treatment
without PDE5 inhibitors (n ¼ 8)
PVR, WU 6.7  0.9 6.2  0.8 6.7  0.9 6.6  1.0 7.2  0.9 6.8  0.9 7.0  1.0 6.7  1.0
CO, l/min 5.4  0.3 5.6  0.4 5.6  0.4 5.7  0.5 5.2  0.3 5.3  0.4 5.3  0.4 5.4  0.5
HR, beats/min 68  4.1 66  4.4 66  4.3 66  4.1 68  4.9 69  5.1 68  4.6 70  5.0
mPAP, mm Hg 42  2.5 40  3.1 41  3.7 42  3.5 43  3.2 42  3.6 42  3.8 41  3.7
SV, ml 81  5.6 86  6.1 85  5.8 87  6.8 79  5.7 79  5.3 79  5.8 80  7.6
MAP, mm Hg 92  4.6 85  3.8 93  5.9 89  5.5 90  5.8 88  5.4 88  4.7 89  6.3
SVR, dyne 1,303  72 1,185  121 1,322  164 1,238  181 1,348  160 1,295  160 1,316  184 1,300  163
Values are mean  SEM.
HR ¼ heart rate; other abbreviations as in Table 1.
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FIGURE 1 Hemodynamic Changes During Apelin Infusion in Patients With PAH
Hemodynamic changes during infusion of (Pyr1)apelin-13 (solid squares) or matched saline placebo (open squares) in patients with pulmonary
arterial hypertension (PAH) in pulmonary vascular resistance (PVR), cardiac output, mean pulmonary artery pressure (mPAP), heart
rate, systemic vascular resistance (SVR), and mean arterial pressure (MAP). Data are reported as mean  SEM. *p ¼ 0.0089, **p ¼ 0.002,
***p < 0.0006, §p ¼ 0.0001, and #p # 0.0001 2-way analysis of variance with post hoc Bonferroni tests. bpm ¼ beats per minute.
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FIGURE 2 Effect of Apelin and Exercise on PVR
Pulmonary vascular resistance during infusion of (Pyr1)apelin-13 or matched saline pla-
cebo in patients with pulmonary arterial hypertension while undergoing exercise pro-
tocol. A zero reflects resting measurements, raise reflects measurements taken with legs
raised in ergometers pedals at rest, then further measurements at 20% and 40% of
previous erect maximal cardiopulmonary exercise test performance. Data are reported
as mean  SEM. *p ¼ 0.019, 2-way analysis of variance with post hoc Bonferroni tests.
PVR ¼ pulmonary vascular resistance.
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7HEMODYNAMIC OUTCOMES. No time-order effects
were observed. In comparison to saline placebo,
(Pyr1)apelin-13 infusion reduced PVR (p < 0.0001)
with an effect that appeared maximal at 30 nmol/min
(Figure 1). (Pyr1)apelin-13 infusion increased CO
(Figure 1) (p < 0.0001) and stroke volume (SV) (data
not shown) but did not affect mean pulmonary artery
pressure, pulmonary arterial wedge pressure, or heart
rate (Figure 1). Contrary to previous systemic studies
(11,13), (Pyr1)apelin-13 did not cause a significant
reduction in SVR (Figure 1).
EXERCISE. During exercise (n ¼ 9), there were no
differences in any of the hemodynamic variables
except PVR (Figure 2) and heart rate. The increase in
PVR was attenuated during (Pyr1)apelin-13 infusion
(p < 0.05), and this was associated with an increase in
heart rate (p < 0.01).
EFFECT OF CONCOMITANT PDE5 INHIBITORS. On
post hoc analysis, there was a more marked reduction
in PVR (reduction by 1.4 WU versus 0.4 WU) (p <
0.0001) and increase in CO (increase by 0.6 l/min vs.
0.35 l/min) (p < 0.0001) (Figure 3) with (Pyr1)apelin-13
when compared with saline placebo in patients who
were already established on treatment with
phosphodiesterase-5 (PDE5) inhibitors (n ¼ 11). This
group also showed a reduction in SVR (data not
shown; p ¼ 0.0009). There was no change in these
variables for patients who were not established on
PDE5 inhibitors (Figure 3).
DISCUSSION
In patients with PAH, we have demonstrated for
the first time that short-term intravenous (Pyr1)
apelin-13 infusion associated with improvements in
pulmonary hemodynamics, including a fall in PVR
and an increase in CO and stroke volume. This
effect was seen even in those patients already on
medication for pulmonary hypertension and was
particularly prominent in patients maintained on
concomitant PDE 5 inhibitor therapy, consistent
with an effect on cyclic GMP. We believe that
apelin agonism is a potentially important and novel
therapeutic target for intervention in patients with
PAH.
The current recommendations for treatment goals
as set out at the fifth World Symposium on
Pulmonary Hypertension advise normalization of right
ventricular function which is defined as right atrial
pressure <8 mmHg and cardiac index of >2.5 l/min/m2
(22). We have demonstrated that intravenous (Pyr1)
apelin-13 infusion was able to improve CO and reduce
PVR in patients with PAH. This suggests that, in addition
to standard therapy, apelin agonism may have apotential role in helping these patients achieve their
therapeutic targets.
This study was designed as an invasive study
because this is the most accurate method of deter-
mining changes in hemodynamic variables. The study
design was a within-subject, blinded, randomized,
crossover study in order to enhance statistical power
and robust comparisons of effects. We designed the
study to measure both resting and exercise hemody-
namics because patients with PAH are more symp-
tomatic during activity, and we hoped to demonstrate
that apelin has therapeutic benefit both at rest and
during exercise. Interestingly, we were able to
demonstrate improvements in pulmonary hemody-
namics at rest, but surprisingly, improvements were
not greater when the subjects exercised. This may be
because of the large changes in hemodynamics
caused by exercise, which may have obscured the
more subtle changes observed at rest. It may be that
longer-term apelin agonism could lead to an
improvement in exercise pulmonary hemodynamics,
and this may be worth examining in future studies.
The apelin system may have major relevance for
patients with PAH. Dysfunction of bone morphoge-
netic protein (BMP) signaling is an important pathway
in the pathogenesis of PAH (23), and it appears to
influence apelin production as a potential mediator of
the pathogenesis of PAH. In a long-term hypoxic
FIGURE 3 Patients With or Without PDE5 Inhibitor Treatment
Hemodynamic changes during infusion of (Pyr1)apelin-13 (solid squares) or matched saline placebo (open squares) in patients with pulmonary
arterial hypertension who are (A) on treatment with PDE5 inhibitors or (B) not on treatment with PDE5 inhibitors. Data are reported as
mean  SEM. *p ¼ 0.049, **p ¼ 0.0127, *** p ¼ 0.0042, §p ¼ 0.0039, §§p ¼ 0.0017, #p ¼ 0.0011, ##p ¼ 0.0003, 2-way analysis of
variance with post hoc Bonferroni tests. Abbreviations as in Figure 1.
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9rodent model of right ventricular failure (24), apelin
had inotropic effects, and treating rats with
monocrotaline-induced pulmonary hypertension
with an apelin infusion led to improved right ven-
tricular mass and hemodynamic variables (14). In
human studies, apelin expression is reduced in the
pulmonary artery endothelial cells (PAECs) of pa-
tients with idiopathic pulmonary arterial hyperten-
sion (15). Reducing apelin in human PAEC by siRNA
impairs PAEC survival and promotes pulmonary ar-
tery smooth muscle cell proliferation in man (15).
Furthermore, apelin can directly suppress vascular
smooth muscle cell proliferation in response to
growth factors, and is proapoptotic (15). Importantly,
long-term apelin administration was associated with
positive inotropism without any evidence of
myocardial hypertrophy in murine models of PAH (6).
In previous studies, we provided the first evidence
that apelin has vasoactive actions in humans. We
showed that apelin causes vasodilatation in vivo in
the human forearm circulation of healthy volunteers
through a predominantly NO-dependent mecha-
nisms, and that this effect is preserved in patients
with heart failure (11,13). Furthermore, we showed
that apelin is a direct coronary vasodilator and in-
creases myocardial contractility in humans. It caused
a reduction in both peak and end-diastolic left ven-
tricular pressures (13). Here, we show that similar
effects are also seen in pulmonary hemodynamics in
patents with PAH.
It is also noted that there is not a dose-effect
relationship, with a plateauing of PVR and CO at the
higher infusion rates (Figure 1). This is consistent with
results seen in our previous studies (13) and is why we
had chosen to reduce the doses of our infusion rates
during this study. This may reflect the doses we have
chosen or an “all or nothing” effect.
We included patients who were taking PDE5 in-
hibitors in this study. It is known that in ex vivo
myography studies, inhibition of NO attenuated
apelin-induced vasorelaxation in human mesenteric
arteries (5). As we demonstrated in our previous
clinical study (11), the effects of apelin are partially
attenuated with an “NO clamp” (concomitant
balanced infusion of a NO donor and a NO synthase
inhibitor) suggesting that apelin causes arterial
vasodilation via a NO-dependent manner. PDE5 in-
hibitors also act on the NO pathway by preventing
degradation of cGMP. We felt it was important to
include this group for recruitment in our study to
determine whether there was any synergistic vaso-
dilatory effect when combining 2 drugs that act on the
NO-cGMPpathway. Interestingly, on post hoc analysis,the group of patients established on PDE5 inhibitors
had more marked improvements in PVR, CO, and SV,
whereas the group who were not on treatment with
PDE5 inhibitors (includes treatment naive and those
on treatments other than PDE5 inhibitors) showed no
demonstrable effect. This study was not powered to
investigate this effect directly, but it would be impor-
tant for future studies to explore this interaction
further. It should also be noted that the group on PDE5
inhibitors had more severe baseline hemodynamic
abnormalities, and demonstrated a reduction in SVR
with apelin infusion consistent with our previous ob-
servations in patients with heart failure (11,13). It was
not possible to assess the symptomatic impact of these
short-term changes in the patients as they were supine
on the catheterization table.
Currently, there is a great deal of interest in upfront
combination treatment for PAH to determine whether
this has long-term beneficial effects in patients with
PAH by the establishment of early control and preser-
vation of RV function. These benefits need to be
balanced with the potential for drug–drug interactions
and potential adverse effects. We did not demonstrate
any adverse effects in our study, but this would need to
be explored further in long-term studies.
This study examined the short-term effects of
apelin administration, and longer studies are
needed to determine long-term hemodynamic ben-
efits, as well as potential long-term adverse effects.
We have previously determined the effect of pro-
longed systemic infusion of apelin in man. During
6-h infusions of apelin in healthy volunteers and
patients with heart failure, apelin was well tolerated
and its inotropic actions were maintained, with a
sustained increase in cardiac index and left ven-
tricular ejection fraction (12). Furthermore, we pre-
viously monitored pulmonary artery blood flow
during the first hour of apelin infusion using echo-
cardiography and found this to be increased with
apelin infusion versus saline placebo. This suggests
that apelin will have sustained benefits on pulmo-
nary vascular hemodynamics.
Apelin has also been shown in preclinical studies to
target pulmonary vascular remodeling (15), so not
only does it have beneficial hemodynamic effects in
the human pulmonary vasculature, but it may also
prevent the pulmonary vasculature remodeling seen
in PAH. However, this has yet to be established.
(Pyr1)apelin-13 peptide is unlikely to represent a
viable long-term therapeutic intervention for PAH
because it would require continuous intravenous
systemic infusion. However, our study has demon-
strated that activation of the apelin-APJ pathway
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: This
study has shown that APJ agonism reduces PVR
and increases CO in patients with PAH in the
short-term setting. Post hoc analysis suggests
that these hemodynamic changes may be enhanced in
those patients on concomitant phosphodiesterase-5
inhibitors.
TRANSLATIONAL OUTLOOK: Further research is
required to look at the long-term effects of APJ
agonism on patients with PAH. Development of an
oral preparation that can cause prolonged APJ
agonism will be necessary to allow further research
into the effects of long-term APJ agonism and to
consider APJ agonism as a potential treatment for
patients with PAH.
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10led to an important improvement in PVR and CO
even in patients established on current PAH thera-
pies. To make apelin agonism a viable potential
treatment for patients with PAH, further drug
development is required to develop an oral or
inhaled preparation that can be easily delivered to
enable prolonged apelin agonism, in order to avoid
the difficulties of long-term infusion treatments
well demonstrated with prostacyclin. Development
of orally active drugs that can cause long-term
apelin agonism would be an exciting approach to
the treatment of PAH. There are already synthetic
agonists of the apelin receptor showing some
promise in research (25).
CONCLUSIONS
We have shown here that short-term apelin infusion
reduces PVR and increase CO and stroke volume in
patients with PAH. Due to its short-term hemody-
namic effects, the apelin pathway may be an
exciting potential therapeutic target for the treat-
ment of PAH. Further studies are required to
determine the long-term effects of APJ agonism in
PAH, and development of an oral or inhaled prep-
aration that can easily deliver prolonged apelin
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